Farxiga Lowers HbA1c by 0.5-0.7% and Fasting Blood Sugar by 20-30 mg/dL
Farxiga (dapagliflozin) reduces HbA1c by approximately 0.5% with the 5 mg dose and 0.7% with the 10 mg dose, and lowers fasting plasma glucose by 20-30 mg/dL compared to placebo. 1
Glycemic Reduction Details
HbA1c Reduction
The FDA label data demonstrates consistent HbA1c reductions across multiple clinical scenarios 1:
- Monotherapy or with metformin: 0.5-0.7% reduction with 10 mg dose
- With insulin: 0.5-0.6% reduction
- With DPP-4 inhibitors: 0.45-0.48% reduction
- With thiazolidinediones: 0.4-0.6% reduction depending on dose
- In moderate renal impairment (eGFR 45-60): 0.3-0.4% reduction
The SGLT2 inhibitor class as a whole demonstrates HbA1c reductions ranging from 0.4% to 1%, with dapagliflozin specifically showing 0.5-0.7% reductions in most trials 2.
Fasting Plasma Glucose Reduction
Farxiga consistently lowers fasting blood sugar by 20-30 mg/dL across different patient populations 1:
- With metformin: -24 to -29 mg/dL
- With insulin: -22 to -25 mg/dL
- With DPP-4 inhibitors: -24 mg/dL
- With thiazolidinediones: -24 to -30 mg/dL
Goal Achievement Rates
Approximately 35-60% of patients achieve an HbA1c below 7% when treated with dapagliflozin, with higher success rates at the 10 mg dose 2. In the FDA trials, specific achievement rates ranged from 26-39% depending on baseline HbA1c and combination therapy 1.
Important Clinical Context
Dose-Response Relationship
The 10 mg dose consistently produces greater glucose lowering than the 5 mg dose. In pediatric trials, patients with HbA1c ≥7% at week 14 were uptitrated from 5 mg to 10 mg to achieve better control 1.
Baseline HbA1c Matters
Patients with higher baseline HbA1c (>9%) are more likely to experience weight gain rather than weight loss, despite glucose improvement 3. This is a critical counseling point—when baseline HbA1c is very elevated, focus intensively on diet and exercise to prevent paradoxical weight gain.
Hypoglycemia Risk
The hypoglycemia risk with Farxiga alone is minimal due to its insulin-independent mechanism 2. However, when combined with sulfonylureas or insulin, hypoglycemia rates increase (12.8% vs 3.7% with placebo when added to metformin plus sulfonylurea) 4.
Renal Function Considerations
In patients with moderate renal impairment (eGFR 45-60), glucose lowering is more modest (0.3% HbA1c reduction) but still clinically meaningful 1, 5. There is an initial eGFR drop of approximately 2-5 mL/min that returns to baseline within 3 weeks of stopping the medication 5.
Additional Metabolic Effects
Beyond glucose lowering, Farxiga produces:
- Weight loss: 1.5-2.1 kg compared to placebo 1
- Blood pressure reduction: 2-4 mmHg systolic 6, 1
- Improved glycemic variability: Reduced time above range and increased time in range 7
Clinical Pitfalls to Avoid
Do not expect dramatic glucose reductions—this is a modest glucose-lowering agent (0.5-0.7% HbA1c reduction). Its primary value lies in cardiovascular and renal protection, not aggressive glucose control 2, 6.
Watch for paradoxical weight gain in patients with very poor baseline control (HbA1c >9%). These patients need aggressive lifestyle intervention alongside medication 3.
Monitor for genital and urinary tract infections, which occur more frequently than with placebo (genital infections: 5.5% vs 0%; UTIs: similar rates but slightly elevated in some studies) 4, 8.